FOSUNPHARMA：2023FIRSTQUARTERLYREPORT.pdf

《FOSUNPHARMA：2023FIRSTQUARTERLYREPORT.pdf》由会员分享，可在线阅读，更多相关《FOSUNPHARMA：2023FIRSTQUARTERLYREPORT.pdf（22页珍藏版）》请在三个皮匠报告上搜索。

1、Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for thecontents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim anyliability whatsoever for any loss howsoever arising from or in reliance

2、 upon the whole or any part of the contents of thisannouncement.上 海 復 星 醫 藥（集 團）股 份 有 限 公 司Shanghai Fosun Pharmaceutical(Group)Co.,Ltd.*(a joint stock company incorporated in the Peoples Republic of China with limited liability)(Stock Code:02196)2023 FIRST QUARTERLY REPORTThis announcement is made p

3、ursuant to Rule 13.09(2)and Rule 13.10B of the Rules Governing theListing of Securities on The Stock Exchange of Hong Kong Limited and the Inside InformationProvisions under Part XIVA of the Securities and Futures Ordinance(Cap.571 of the Laws of HongKong).The following is the 2023 first quarterly r

4、eport of Shanghai Fosun Pharmaceutical(Group)Co.,Ltd.*(the Company,together with its subsidiaries,collectively the Group)(the 2023 First QuarterlyReport)for the three months ended 31 March 2023(the Reporting Period).The financial reporttherein is prepared in accordance with the PRC Accounting Standa

5、rds for Business Enterprises and isunaudited.By order of the BoardShanghai Fosun Pharmaceutical(Group)Co.,Ltd.*Wu YifangChairmanShanghai,the Peoples Republic of China28 April 2023As at the date of this announcement,the executive directors of the Company are Mr.Wu Yifang,Mr.Wang Kexin,Ms.Guan Xiaohui

6、 and Mr.Wen Deyong;the non-executive directors of the Company are Mr.Chen Qiyu,Mr.Yao Fang,Mr.Xu Xiaoliang and Mr.Pan Donghui;and the independent non-executive directors of the Company are Ms.Li Ling,Mr.Tang Guliang,Mr.Wang Quandi and Mr.Yu Tze Shan Hailson.*for identification purposes only 1 I.IMPO